These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16116136)

  • 21. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
    Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
    Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myasthenia gravis and scleroderma.
    Bhalla R; Swedler WI; Lazarevic MB; Ajmani HS; Skosey JL
    J Rheumatol; 1993 Aug; 20(8):1409-10. PubMed ID: 8230029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.
    Chaudhry V; Cornblath DR; Griffin JW; O'Brien R; Drachman DB
    Neurology; 2001 Jan; 56(1):94-6. PubMed ID: 11148242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of myasthenia gravis pseudoparalytica].
    Rüster M; Dietel K
    Kinderarztl Prax; 1970 Jul; 38(7):309-12. PubMed ID: 5523869
    [No Abstract]   [Full Text] [Related]  

  • 26. Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Siddiqi ZA
    Ann N Y Acad Sci; 2008; 1132():249-53. PubMed ID: 18567876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary lymphoma of CNS, mycophenolate mofetil and lupus.
    Finelli PF; Naik K; DiGiuseppe JA; Prasad A
    Lupus; 2006; 15(12):886-8. PubMed ID: 17211996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil.
    Termsarasab P; Katirji B
    J Neuroimmunol; 2012 Aug; 249(1-2):83-5. PubMed ID: 22613699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dermatomyositis and myastenia gravis: An uncommon association with therapeutic implications.
    Sangüesa Gómez C; Flores Robles BJ; Méndez Perles C; Barbadillo C; Godoy H; Andréu JL
    Reumatol Clin; 2015; 11(4):244-6. PubMed ID: 25498320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of refractory generalized myasthenia gravis with rituximab.
    Lebrun C; Bourg V; Tieulie N; Thomas P
    Eur J Neurol; 2009 Feb; 16(2):246-50. PubMed ID: 19146644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.
    Meriggioli MN; Rowin J; Richman JG; Leurgans S
    Ann N Y Acad Sci; 2003 Sep; 998():494-9. PubMed ID: 14592919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis.
    Lai GG; Koo YX; Tao M; Tan TT; Lim ST
    Acta Oncol; 2011 Jan; 50(1):144-5. PubMed ID: 20670084
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection.
    Caponnetto C; Rossi E; Primavera A
    Eur Neurol; 2001; 46(1):53-4. PubMed ID: 11455187
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunosuppressive therapies in myasthenia gravis.
    Sanders DB; Evoli A
    Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical treatment options for ocular myasthenia gravis.
    Antonio-Santos AA; Eggenberger ER
    Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myasthenia gravis and specific immunotherapy: monoclonal antibodies.
    Cai XJ; Li ZW; Xi JY; Song HZ; Liu J; Zhu WH; Guo Y; Jiao Z
    Ann N Y Acad Sci; 2019 Sep; 1452(1):18-33. PubMed ID: 31393614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature.
    Rezania K; Soliven B; Baron J; Lin H; Penumalli V; van Besien K
    Leuk Lymphoma; 2012 Mar; 53(3):371-80. PubMed ID: 21864038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iatrogenic immunodeficiency-associated lymphoproliferative disorder secondary to mycophenolate mofetil treatment in a patient with myasthenia gravis.
    Zha K; Silvestri NJ
    Muscle Nerve; 2022 Apr; 65(4):E14-E16. PubMed ID: 34993978
    [No Abstract]   [Full Text] [Related]  

  • 40. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
    Kupersmith MJ; Ying G
    Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.